QT-prolongation in Psychiatric Hospitals

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02043925

Enrollment

152

Registered

2014-01-23

Start date

2010-10-31

Completion date

2015-03-31

Last updated

2015-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

QT-prolongation

Keywords

QT-prolongation, Torsade de Pointes, drug interactions, psychiatry

Brief summary

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Interventions

DRUGdrugs linked with QT-prolongation

all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* inpatient in one of the 6 participating psychiatric hospitals * QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug

Exclusion criteria

* age \< 18 year

Design outcomes

Primary

Measure	Time frame
change in QTc-interval (corrected for heart rate)	before and one week after the start of a QT-prolonging drug

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026